Sign in to view content

Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial

Rajiv Anand, MD, FRCS, FASRS

Video
Published 2024

Related

Hereditary Retinal Disease & Genetics Take-Home Panel
David Sarraf, MD
Annual Meeting Talks
2019
Surgical Case Conference: Sengul Ozdek, MD, FEBO, FASRS
Sengul Ozdek, MD, FEBO, FASRS
Annual Meeting Talks
2024
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Updates from the Field
2020

Category: Hereditary Retinal Disease & Genetics

See more